Challenging issues in the management of cancer-associated venous thromboembolism

Abstract

Venous thromboembolism (VTE) is a common complication among patients with cancer and is associated with delays in underlying cancer treatment and increases in morbidity and mortality. Acute and long-term treatments with low-molecular-weight-heparin (LMWH) have been recommended as a standard of care for patients with cancer with VTE for the past 20 years. Direct oral anticoagulants (DOACs) have recently emerged as a new therapeutic modality for cancer-associated VTE because of the convenience of oral administration and rapid onset of action. Our knowledge regarding DOACs for cancer-associated VTD has expanded in recent years. Thus, this study aimed to review recent major pivotal trials comparing DOACs with LMWH for managing cancer-associated VTE. Moreover, a recently updated understanding of DOACs in the treatment of cancer-associated VTE in specific challenging situations is presented.

Thrombosis Attack in a Cancer Patient: A Case Report

“…Patients with cancer associated with VTE have a higher risk for complications such as recurrence of VTE and major bleeding than those without cancer. VTE developing in patients with cancer is associated with two to six times increased risk of mortality [14].…”

Cancer Patient was attacked by Thrombosis: Case Report

“…Patients with cancer associated VTE have higher risk for complications such as recurrence of VTE and major bleeding than those without cancer. VTE developing in patients with cancer is associated with two to six times increased risk of mortality [14].…”